Colony-stimulating factors: a new step in clinical practice. Part II
Related Experiment Video
Updated: Nov 7, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
1Hematopoiesis Program, Western Pennsylvania Cancer Institute, West Penn Hospital, Pittsburgh 15224.
Abstract:
Clinical application of colony-stimulating factors (CSFs) such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) are advancing rapidly now that these factors are approved as indicated therapy in patients with chemotherapy-induced neutropenia, patients undergoing autologous bone marrow transplantation (BMT) and patients who develop graft failure after BMT. Novel CSFs are also being explored for potential clinical application in situations not as significantly affected by rhG-CSF or rhGM-CSF. Studies determining unique effects of novel factors, combinations of factors and combinations with peripheral blood progenitor cell fusions which may lead to future clinical applications of CSFs will be reviewed.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

